NasdaqGS:IMCRBiotechs
A Look At Immunocore (IMCR) Valuation After J.P. Morgan Update And Analyst Upgrade
Immunocore Holdings (IMCR) has come into focus after its appearance at the 44th Annual J.P. Morgan Healthcare Conference, where it outlined 2026 goals and highlighted cash resources supporting its clinical pipeline.
See our latest analysis for Immunocore Holdings.
Despite the conference update and recent rating upgrade, Immunocore’s share price return over the past month shows a 10.33% decline. Its 1 year total shareholder return of 8.55% contrasts with a 3 year total shareholder return...